Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial
Part of paid clinical trials in Houston, Texas.
- Sponsor
- M.D. Anderson Cancer Center
- Study ID
- NCT07610525
- Phase
- PHASE2
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Blood and Image Guided
- Optimization of Neoadjuvant Therapy
- Phase 2
- Triple Negative Breast Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Paclitaxel + Carboplatin — DRUGGiven by IV
- Pembrolizumab — DRUGGiven by IV
Study Details
To learn whether certain blood and imaging tests can show which people with early-stage TNBC may already have had a complete response to chemotherapy before they go to surgery.
Key Dates
- Start date
- Nov 5, 2026
- Status verified
- May 2026
- Primary completion
- Jan 15, 2029
- Completion
- Jan 15, 2031
Study Design
- Enrollment
- 200 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Cohort A1Cohort A1 Omiting AC/PB: Paclitaxel+Carboplatin+Pembrolizumab x 4 cycles
- Experimental: Cohort A2Cohort A2 Receiving AC/PB: Paclitaxel+Carboplatin+Pembrolizumab x 4 cycles + (AC/PB) x 4 cycles
- Experimental: Cohort B1Cohort B1 Receiving AC/PB: Paclitaxel+Carboplatin+Pembrolizumab x 4 cycles + (AC/PB) x 4 cycles
- Experimental: Cohort B2Cohort B2 Omiting AC/PB: Paclitaxel+Carboplatin+Pembrolizumab x 4 cycles
Primary Outcome Measure
Safety and adverse events (AEs). [ Time Frame: Through study completion; an average of 1 year ]
Central Contacts
- Akshara S Raghavendra, MD713-792-2817
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| MD Anderson Cancer Center | Houston | Texas | 77030 | Clinton Yam, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Houston, TX
By condition
By specialty
By research site
Related Studies
- The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)PHASE1/PHASE2 · Recruiting · PMV Pharmaceuticals, Inc · Irvine, California
- Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab AdizutecanPHASE1 · Recruiting · AbbVie · Duarte, California
- Correlation of Clinical Response to Pathologic Response in Patients With Early Breast CancerPHASE2 · Recruiting · Baylor Breast Care Center · Houston, Texas
- A Beta-only IL-2 ImmunoTherapY StudyPHASE1/PHASE2 · Recruiting · Medicenna Therapeutics, Inc. · San Diego, California